You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Medtronic
Dow
Colorcon
AstraZeneca

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

CLARITIN HIVES RELIEF REDITAB Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Claritin Hives Relief Reditab patents expire, and when can generic versions of Claritin Hives Relief Reditab launch?

Claritin Hives Relief Reditab is a drug marketed by Bayer Healthcare Llc and is included in one NDA.

The generic ingredient in CLARITIN HIVES RELIEF REDITAB is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and nineteen suppliers are listed for this compound. Additional details are available on the loratadine profile page.

US ANDA Litigation and Generic Entry Outlook for Claritin Hives Relief Reditab

A generic version of CLARITIN HIVES RELIEF REDITAB was approved as loratadine by PLD ACQUISITIONS LLC on January 21st, 2003.

  Start Trial

Summary for CLARITIN HIVES RELIEF REDITAB
Drug patent expirations by year for CLARITIN HIVES RELIEF REDITAB
Paragraph IV (Patent) Challenges for CLARITIN HIVES RELIEF REDITAB
Tradename Dosage Ingredient NDA Submissiondate
CLARITIN HIVES RELIEF REDITAB TABLET, ORALLY DISINTEGRATING;ORAL loratadine 020704
CLARITIN REDITABS TABLET, ORALLY DISINTEGRATING;ORAL loratadine 020704

US Patents and Regulatory Information for CLARITIN HIVES RELIEF REDITAB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare Llc CLARITIN HIVES RELIEF REDITAB loratadine TABLET, ORALLY DISINTEGRATING;ORAL 020704-003 Nov 19, 2003 OTC Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CLARITIN HIVES RELIEF REDITAB

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1110543 SPC/GB08/005 United Kingdom   Start Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
0152897 C00152897/01 Switzerland   Start Trial FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0152897 SPC/GB01/012 United Kingdom   Start Trial PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Dow
McKinsey
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.